Ensayos clínicos y estudios traslacionales gracias a Twist

Shubha Anand | Universidad de Cambridge

alt text
Presentado por
Shubha Anand
Shubha Anand
Directora, Laboratorio de Diagnóstico Molecular del Cáncer, Universidad de Cambridge
Ezequiel Martin
Ezequiel Martin
Bioinformático sénior, Universidad de Cambridge

Cubierto en este seminario web
Cómo el Laboratorio de Diagnóstico Molecular del Cáncer está utilizando paneles basados en capturas de TWIST Bioscience para el análisis molecular en 3 ensayos
Un panel pantumoral de 350 genes para realizar la secuenciación de muestras emparejadas tumorales y de la línea germinal (tejidos fijados en formol e incluidos en parafina) para el ensayo BoB
Un panel mieloide de 56 genes para investigar una asociación entre la hematopoyesis clonal y la enfermedad grave de la COVID-19
Un panel de linfoma de 150 genes que se está probando en ADNtc para un ensayo del linfoma difuso de linfocitos B grandes (DLBCL)

The Cancer Molecular Diagnostics Laboratory is based in University of Cambridge, Department of Oncology and is funded by NIHR Cambridge Biomedical Research Centre, The Mark Foundation for Cancer Research & The Cancer Research UK Cambridge Centre. The laboratory supports translational research studies and clinical trials taking place in the Cambridge Biomedical Campus. In this talk we will be showing how we are using three capture-based panels from TWIST Bioscience for molecular analysis in three different trials. We are utilizing a 350-gene pan-cancer panel to perform sequencing of matched germline and tumour samples (FFPE) for the Basket of Baskets (BoB) trial of Cancer Core Europe (CCE). In addition, we have a 56-gene myeloid panel designed by Prof. G Vassiliou at the Dept. of Haematology, University of Cambridge, who is investigating an association between Clonal Haematopoiesis and Severe COVID-19 disease. Lastly, we are also testing a 150-gene lymphoma panel on ctDNA for a Diffuse Large B cell lymphoma (DLBCL) trial (Lead PI: Dr Dan Hodson, Dept. of Haematology, University of Cambridge) to establish a platform for precision medicine in DLBCL.

Comparta sus datos con nosotros para ver el seminario web

 

 

Powered by Translations.com GlobalLink Web Software